Pharmaceutical Product Development, which provides contract research services companies to pharma and biotech companies worldwide, has returned to the public markets. Its IPO, on Thursday, February 6, came eight-plus years after Hellman & Friedman and Carlyle completed its leveraged buyout of the company. The result? PPD’s IPO assigned it an initial enterprise value close to $14 billion, up from the $3.6 billion valuation at which it was valued in its December 2011 take-private transaction.
Read the full article: Hellman & Friedman’s PPD Shows PE Growth in Action //